Transcenta Holding Limited (HK:6628)
:6628
Want to see HK:6628 full AI Analyst Report?
Top Page
Transcenta Holding Limited
(6628)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$1.50
▼(-33.33% Downside)
Action:Reiterated
Date:05/11/26
The score is weighed down primarily by weak financial performance (shrinking revenue, negative gross profit, persistent losses and cash burn) and bearish technicals (price below key moving averages with negative MACD). Valuation contributes only modestly because the negative P/E reflects loss-making operations and dividend yield data is unavailable.
Positive Factors
Vertical integration / CMC capability
Transcenta’s integration from discovery through CMC and commercialization gives it durable control of development timelines and manufacturing scale-up. Owning biologics process development reduces reliance on external partners, supports faster clinical-to-commercial transitions and can protect margins over the medium term.
Negative Factors
Material revenue decline
A material top-line contraction limits scale and operating leverage critical for a development-stage biopharma. Lower revenue reduces internal funding capacity for R&D and commercialization, increases reliance on external financing, and heightens execution risk for advancing multiple pipeline programs over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Vertical integration / CMC capability
Transcenta’s integration from discovery through CMC and commercialization gives it durable control of development timelines and manufacturing scale-up. Owning biologics process development reduces reliance on external partners, supports faster clinical-to-commercial transitions and can protect margins over the medium term.
Read all positive factors
Transcenta Holding Limited (6628) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$863.76M
Dividend YieldN/A
Average Volume (3M)1.29M
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth-33.80%
EPS Growth31.52%
CountryHK
Employees184
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.64
Shares Outstanding455,375,000
10 Day Avg. Volume1,161,500
30 Day Avg. Volume1,285,964
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.28
Price to Sales (P/S)108.90
P/FCF Ratio-5.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.76
Revenue Forecast (FY)HK$15.24M
Transcenta Holding Limited Business Overview & Revenue Model
Company Description
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company devel...
How the Company Makes Money
null...
Transcenta Holding Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.41M | 7.24M | 11.26M | 53.85M | 101.89M | 50.24M |
| Gross Profit | 3.27M | -40.75M | 4.00M | 14.40M | 19.89M | 9.37M |
| EBITDA | -211.90M | -153.11M | -233.12M | -393.01M | -334.09M | -1.65B |
| Net Income | -266.36M | -198.45M | -290.29M | -462.57M | -406.75M | -1.72B |
Balance Sheet | ||||||
| Total Assets | 1.04B | 925.23M | 1.20B | 1.69B | 2.13B | 2.54B |
| Cash, Cash Equivalents and Short-Term Investments | 45.81M | 14.15M | 169.42M | 546.03M | 895.45M | 1.22B |
| Total Debt | 210.14M | 126.26M | 250.61M | 409.63M | 411.46M | 364.71M |
| Total Liabilities | 386.57M | 306.87M | 448.64M | 665.67M | 660.64M | 579.39M |
| Stockholders Equity | 652.13M | 618.36M | 751.64M | 1.03B | 1.47B | 1.97B |
Cash Flow | ||||||
| Free Cash Flow | -175.14M | -142.97M | -216.15M | -373.80M | -318.03M | -457.84M |
| Operating Cash Flow | -170.07M | -135.67M | -213.83M | -358.04M | -295.81M | -384.50M |
| Investing Cash Flow | 8.23M | 55.48M | 14.28M | 57.47M | -102.61M | -69.77M |
| Financing Cash Flow | -157.75M | -74.93M | -178.06M | -47.20M | 26.72M | 879.71M |
Transcenta Holding Limited Technical Analysis
Negative
2.25
Price Trends
2.36
Negative
2.32
Negative
2.92
Negative
Market Momentum
-0.16
Positive
34.55
Neutral
29.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6628, the sentiment is Negative. The current price of 2.25 is above the 20-day moving average (MA) of 2.13, below the 50-day MA of 2.36, and below the 200-day MA of 2.92, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 34.55 is Neutral, neither overbought nor oversold. The STOCH value of 29.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6628.
Transcenta Holding Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$3.38B | -16.22 | -14.53% | ― | -32.12% | -393.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$3.32B | -6.73 | 11.40% | ― | -90.96% | 77.66% | |
47 Neutral | HK$1.33B | -3.96 | -102.50% | ― | 557.36% | -24.06% | |
44 Neutral | HK$863.76M | ― | -27.44% | ― | -33.80% | 31.52% | |
44 Neutral | HK$639.68M | -2.18 | 191.92% | ― | -100.00% | 77.06% | |
44 Neutral | HK$1.82B | -7.60 | -27.70% | ― | -100.00% | 50.29% |
* Healthcare Sector Average
HK:6628
Transcenta Holding Limited
1.93
0.47
32.19%
HK:9939
Kintor Pharmaceutical Ltd
2.64
1.21
84.62%
HK:1875
TOT BIOPHARM International Co. Ltd.
4.43
2.60
142.08%
HK:2197
Clover Biopharmaceuticals Ltd.
2.60
2.36
983.33%
HK:2257
Sirnaomics Ltd.
5.85
2.75
88.71%
HK:3681
SinoMab Bioscience Ltd.
1.30
0.04
3.17%
Transcenta Holding Limited Corporate Events
Transcenta Postpones AGM and Adjusts Share Register Closure Dates
May 14, 2026
Transcenta Holding Limited has postponed its 2026 annual general meeting from June 5 to June 30 to allow additional preparation time, shifting the schedule originally outlined in its 2025 annual results and annual report. The company will issue a ...
Transcenta Reports Strong Preclinical Results for LIV1-Targeting ADCs in Breast and Prostate Cancers
Apr 22, 2026
Transcenta Holding Limited has reported new preclinical data for its novel LIV1-targeting antibody-drug conjugate program TST013, including ADC-2 and ADC-3, showing strong anti-tumor activity and favorable tolerability in multiple patient-derived ...
Transcenta Revamps Chinese Stock Short Name and Corporate Logo to Sharpen Biopharma Focus
Apr 8, 2026
Transcenta Holding Limited has announced a change to its Chinese stock short name on the Hong Kong Stock Exchange, effective 13 April 2026, while keeping its English stock short name, company name and stock code unchanged. The move is intended to ...
Transcenta Narrows Annual Loss on Cost Cuts Despite Revenue Decline
Mar 31, 2026
Transcenta reported that revenue fell to RMB7.4 million in 2025 from RMB11.3 million a year earlier, mainly due to lower CDMO service income, while other income also declined on reduced interest earnings. However, research and development as well ...
Transcenta Sets Board Meeting to Approve 2025 Annual Results and Consider Final Dividend
Mar 18, 2026
Transcenta Holding Limited has announced that its board of directors will convene on March 30, 2026, to review and approve the group’s audited annual results for the financial year ended December 31, 2025. The board will also consider whethe...
Transcenta Tightens Costs and Bolsters Liquidity Ahead of Oppenheimer Conference
Feb 24, 2026
Transcenta Holding Limited will present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, where senior executives plan to brief investors on strategic priorities for 2026 and progress in business development. The company recently...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.